Relatório de análise do tamanho, quota e tendências do mercado de exostose hereditária múltipla da América do Norte – Visão geral do setor e previsão para 2031

Análise de mercado da exostose hereditária múltipla

A MHE é uma doença genética rara caracterizada por múltiplos tumores ósseos benignos (osteocondromas), levando a deformidades, dor e restrição de mobilidade em casos graves. Espera-se que a crescente consciencialização sobre as MHE e as condições hereditárias atue como um motor para o crescimento do mercado. Embora as terapias avançadas como o palovaroteno estejam associadas a custos anuais significativos, tornando o tratamento eficaz inacessível para muitos doentes, especialmente aqueles sem cobertura de seguro suficiente. Espera-se que isto atue como uma restrição ao crescimento do mercado.

Tamanho do mercado de exostose hereditária múltipla

O tamanho do mercado norte-americano de exostose hereditária múltipla foi avaliado em 49,82 milhões de dólares em 2023 e deverá atingir os 63,46 milhões de dólares até 2031, com um CAGR de 3,1% durante o período de previsão de 2024 a 2031. Além dos insights sobre cenários de mercado, tais como como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research também incluem análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços e enquadramento regulamentar.

Múltiplas tendências de mercado da exostose hereditária

“Aumentar a Consciencialização e Avanços na Investigação Genética”

O mercado da Exostose Hereditária Múltipla (MHE) da América do Norte está a testemunhar uma tendência significativa para aumentar a consciencialização e os avanços na investigação genética relacionada com a condição. À medida que os profissionais de saúde e os doentes se tornam mais informados sobre a EHM, há uma procura crescente por diagnósticos precisos e opções de tratamento eficazes. Os desenvolvimentos científicos nos testes genéticos e na biologia molecular estão a melhorar a compreensão dos mecanismos subjacentes à EHM, conduzindo a abordagens de medicina personalizada. Além disso, iniciativas educativas melhoradas e esforços de defesa dos doentes estão a contribuir para a proliferação de conhecimentos sobre a EHM, incentivando assim mais indivíduos a procurar aconselhamento médico. Esta mudança não só impulsiona a procura de serviços de saúde especializados, como também alimenta o crescimento do sector farmacêutico, com as empresas a explorarem terapias e intervenções inovadoras destinadas a gerir a EHM de forma mais eficaz. No geral, a convergência da sensibilização, educação e investigação está preparada para moldar significativamente o panorama do mercado de MHE nos próximos anos.

Âmbito do relatório e segmentação        do mercado de exostose hereditária múltipla

Definição de mercado de exostose hereditária múltipla

A Exostose Hereditária Múltipla (EMH), também conhecida como Exostoses Múltiplas Hereditárias (EMH), é uma doença genética caracterizada pelo desenvolvimento de múltiplos tumores ósseos benignos denominados exostoses ou osteocondromas. Surgem geralmente do crescimento da cartilagem nas extremidades dos ossos longos e podem ocorrer em vários locais do corpo. O MHE é geralmente herdado num padrão autossómico dominante; o que significa que apenas é necessária uma cópia do gene mutado para que a doença se manifeste. Os indivíduos com EHM podem sentir dor, complicações decorrentes das exostoses, como deformidades ou restrição de movimentos, e um risco aumentado de desenvolver osteossarcoma, um tipo de cancro ósseo.

Dinâmica de mercado da exostose hereditária múltipla

Motoristas  

• Aumento da prevalência de doenças genéticas    

A MHE é uma doença genética rara caracterizada pelo desenvolvimento de múltiplos tumores ósseos benignos (osteocondromas) que podem causar deformidades físicas, dor e, em casos graves, restrição da mobilidade. À medida que aumenta a consciência sobre a EHM e outras condições hereditárias, aumenta a necessidade de diagnósticos e intervenções terapêuticas eficazes.

Por exemplo,

• In December 2019, according to an article published by National Institutes of Health, the prevalence of HME (Hereditary Multiple Exostoses) in Western populations is estimated to range between 0.4 to 1 per 50,000 individuals. However, among the Chamorro people of Guam, the prevalence is significantly higher, reaching 50 per 50,000. In Western countries, the incidence of this condition is reported to increase by 1.5% annually. This rising prevalence of genetic disorders, such as HME, highlights the growing need for effective treatments, which will drive the North America multiple hereditary exostosis market as healthcare systems prioritize diagnosis and management of such conditions.

With advancements in genetic screening and diagnostics, early detection of MHE is becoming more feasible, which allows for timely intervention and improved patient outcomes. Genetic testing has become a vital tool in identifying carriers and at-risk individuals, enabling personalized treatment plans and targeted therapies. The demand for such diagnostic technologies is growing as more healthcare providers recognize the importance of early diagnosis in managing genetic disorders like MHE.  

• Growing Pediatric Population

Multiple Hereditary Exostosis (MHE) predominantly affects children, typically presenting symptoms during early childhood or adolescence. As the North America pediatric population grows, there is an increased likelihood of more cases being diagnosed, which directly fuels the demand for early diagnosis and effective treatment options. MHE can cause bone deformities, restricted movement, and complications that significantly impact a child's growth and quality of life, making timely intervention essential.

For instance,

• In May 2023, according to an article published by ScienceDirect, India's expanding pediatric population, coupled with increasing affordability, emphasizes the urgent need for improved healthcare services. Although children aged 0 to 18 make up 39% of the population, the highest percentage regionally, healthcare infrastructure remains a critical focus. The substantial pediatric demographic in India highlights the need for specialized healthcare solutions, driving the North America multiple hereditary exostosis market as demand for pediatric genetic disorder diagnosis and treatment rises in this large and growing population.

The expanding pediatric population, particularly in developing regions, has led to a higher focus on pediatric healthcare infrastructure. Governments and healthcare organizations are recognizing the need to strengthen genetic screening programs and offer specialized pediatric care. As more children are diagnosed with MHE, the demand for genetic testing, regular monitoring, and surgical interventions to manage the disorder is rising. This creates a steady need for advanced diagnostic tools and therapeutic options tailored specifically for children.         

Opportunities

• Increase in Patient Care and Support Systems

The increase in patient care and support systems is significantly transforming the North America multiple hereditary exostosis market. As healthcare systems worldwide emphasize patient-centered care, the demand for tailored treatments and comprehensive support has surged. This trend is particularly relevant for MHE, a genetic disorder characterized by the formation of multiple benign bone growths.

With advancements in technology and the rise of telemedicine, patient support systems are becoming more accessible and efficient. Digital platforms allow patients to connect with healthcare professionals, share experiences, and access valuable resources. These developments enable better management of MHE symptoms and promote early intervention, which can mitigate complications. As patients become more informed and empowered, the demand for innovative therapies and management options is likely to increase, creating opportunities for pharmaceutical and biotech companies to expand their product offerings in the MHE market.

• Increase in the Number of Collaborations and Partnerships

The surge in partnerships and collaborations between pharmaceutical companies, research institutions, and medical device manufacturers presents a significant opportunity for the North America multiple hereditary exostosis market. These partnerships can expedite the development of novel treatments and therapies by fostering knowledge sharing, expertise exchange, and resource pooling, in turn addressing the unmet needs of MHE patients.

Companies can combine existing technologies and therapies to create innovative solutions through strategic partnerships. The increase in partnerships and collaborations is likely to drive investment in MHE research, which will, in turn, fuel innovation and growth in the market. As pharmaceutical companies and medical device manufacturers collaborate with other organizations to address the needs of MHE patients, it is expected to witness increased investment in research and development, leading to a greater understanding of the underlying causes of MHE and the development of more effective treatments.

Restraints/Challenges

• High Cost of Advanced Therapies    

The "high cost of advanced therapies" poses a significant restraint on the North America multiple hereditary exostosis (MHE) market due to its multifaceted impact on treatment accessibility and healthcare systems. Advanced therapies, such as palovarotene, come with substantial annual costs making effective treatment unattainable for many, particularly those without adequate insurance coverage. The reliance on costly diagnostic tools like MRI and CT scans, as outlined in the "Diagnosis" section, adds to the financial burden, deterring timely treatment and potentially leading to worse health outcomes.  

 For instance,

• In August 2023, according to an article published by NCBI, the annual cost of palovarotene is estimated to be around USD 622,373 for patients between the ages of 8 and 14, and USD 1,022,894 for those aged 14 and older. This high cost of advanced therapies serves as a major restraint for the North America multiple hereditary exostosis market, as the substantial financial burden limits access to treatment, particularly for patients without sufficient insurance coverage or in regions with constrained healthcare funding.

Limited Availability of Therapies

The limited availability of effective therapies remains a significant restraint on the growth of the North America multiple hereditary exostosis market. Despite advancements in research and the promise shown by emerging drugs like palovarotene, the current therapeutic landscape for MHE is still underdeveloped. Palovarotene, while a promising treatment, is not yet widely available or approved in all regions, limiting its accessibility to a broader patient population.

Moreover, there are very few medications specifically designed to target the underlying causes of MHE. Most available treatments are focused on managing the symptoms, such as pain relief through medications like ibuprofen or surgical interventions to remove osteochondromas. However, these treatments do not address the genetic basis of the disease, leaving patients with limited options for long-term, disease-modifying therapies.

For instance,

• In December 2019, according to an article published by National Institutes of Health, resection, limb shortening, and surgical deformity correction are the only treatment options currently available, primarily recommended in symptomatic cases or when there is suspicion of malignant transformation.

This market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Multiple Hereditary Exostosis Market Scope

The market is segmented based on type, treatment, diagnosis, site, age group, and end user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Sessile
• Pedunculated

Treatment

• Surgery
  • Remove The Tumor
  •  Lengthen Limbs
•  Medication
  • Hospital Pharmacies
  •  Drugs Stores and Retail Pharmacies
  •  Online Pharmacies
•  Others

Diagnosis

• X-Ray
  • Sessile
  •  Pedunculated
•  Computed Tomography (CT) Scan
  • Sessile
  •  Pedunculated
•  Magnetic Resonance Imaging (MRI)
  • Sessile
  •  Pedunculated
•  Genetic Tests
  • Sessile
  •  Pedunculated
•  Others
  • Sessile
  •  Pedunculated

Site

• Legs
• Arms
• Shoulders
• Pelvis
• Fingers
• Toes

Age Group

• Pediatric
• Adult

End User

• Hospitals
  • Private
  • Government
• Specialty Clinics
• Ambulatory Surgical Centers
• Others

Multiple Hereditary Exostosis Market Regional Analysis

The market is analyzed and market size insights and trends are provided by country, type, treatment, diagnosis, site, age group, end user as referenced above.

The countries covered in the market are U.S., Canada, and Mexico.

U.S. is expected to be the dominant and fastest growing country in the market due to its well-established healthcare infrastructure and high adoption rate of advanced technologies, including cloud-based solutions and automation. Supportive government initiatives and significant investments in healthcare IT drive innovation and enhance the efficiency of laboratory operations in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of regional brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Multiple Hereditary Exostosis Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, regional presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

North America Multiple Hereditary Exostosis Market Leaders Operating in the Market Are:

• Bayer AG (Germany)
• Haleon Group of Companies (UK)
• BASF (Germany)
• Viatris Inc. (U.S.)
• Mallinckrodt (U.S.)
• AdvaCare Pharma (U.S.)
• Aurobindo Pharma (India)
• Taj Pharmaceutical Limited (India)
• Wellona Pharma (India)
• ActizaPharma (India)
• Lqms Software Solutions (USA)
• Starlims Corporation (A Subsidiary Of Abbott) (USA)

Latest Developments in North America Multiple Hereditary Exostosis Market

• Em janeiro de 2023, a Ipsen adquiriu a Albireo, reforçando o seu portefólio de doenças raras com o Bylvay (odevixibat), o primeiro tratamento aprovado para a colestase intra-hepática familiar progressiva. Este movimento estratégico visa acelerar o crescimento das doenças hepáticas pediátricas raras, reforçando a presença da Ipsen no mercado e alargando as opções de tratamento para os doentes carenciados.

SKU-73008